Certolizumab pegol

(Cimzia®)

Cimzia®

Drug updated on 9/14/2023

Dosage FormInjection (subcutaneous; 200 mg (200 mg/ml))
Drug ClassTumor necrosis factor (TNF) blocker
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For reducing signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
  • For treatment of adults with moderately to severely active rheumatoid arthritis.
  • For treatment of adult patients with active psoriatic arthritis.
  • For treatment of adults with active ankylosing spondylitis.
  • For treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.
  • For treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Cimzia (certolizumab pegol) Prescribing Information.2022UCB, Inc., Smyrna, GA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines